← Back to Treatments
🏅 FDA Orphan Designation

Respigam

Respiratory syncytial virus immune globulin (Human)

Manufacturer: MedImmune & Massachussetts Public Health Biologics Labs.

Indicated for:
Susceptibility to respiratory infections associated with CD8alpha chain mutationOrphan

FDA-Approved Indications (1)

For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to…

Indications & Usage

For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.